

4FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: Blueberries Medical Corp. (the "Company or "Issuer").

Trading Symbol: BBM

Number of Outstanding Listed Securities: 495,090,087

Date: **March 2026**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Blueberries Medical Corp. ("Blueberries") continues to advance its strategy to become a high-quality, large-scale and highly efficient producer of naturally grown premium quality cannabis ingredients. The Company is positioning itself as a leading Latin American supplier of standardized medicinal-grade cannabis extracts, active pharmaceutical ingredients (APIs) and related products, with its core operations based in the Bogotá Savannah in central Colombia.

Blueberries remains focused on optimizing operational efficiency through cost reductions and disciplined capital allocation. Targeted investments are being made to expand production capacity, enhance manufacturing standards, and improve the quality of its transformation processes. The Company has refined its strategic focus by shifting from full vertical integration across the value chain to the specialized production of high-value, functional cannabis-derived ingredients. To accelerate access to GACP-certified biomass and flower for internal use and resale, Blueberries continues to operate under third-party cultivation agreements with established Colombian growers.

In March 2026, Blueberries continued to advance the reactivation of its pharmaceutical commercial operations in Peru. During the month, the company received new orders from the Peruvian pharmaceutical channel, including THC-based products and additional non-psychoactive products, providing further commercial validation of the market re-entry described in February.

In parallel, Blueberries made technical progress in the business development process with the most relevant client currently in its pharmaceutical pipeline in

Peru. March activities were focused on advancing product-level discussions, documentation requirements, and operational alignment relevant to the client's evaluation and potential purchasing process.

Taken together, these developments indicate continued momentum in the Peruvian pharmaceutical channel, reflected both in new order flow and in the advancement of a strategically relevant pipeline opportunity. The company believes these factors support the ongoing development of recurrent demand in Peru during 2026.

2. Provide a general overview and discussion of the activities of management.
See item #1
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
N/A
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
N/A
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
N/A
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
N/A
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
N/A

8. Describe the acquisition of new customers or loss of customers.
N/A
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.
N/A
10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.
N/A
11. Report on any labour disputes and resolutions of those disputes if applicable.
N/A
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
N/A
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
N/A
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
N/A
16. Provide details of any changes in directors, officers or committee members.
N/A
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
N/A
- Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 6, 2026

Thomas Rodriguez Prats
Name of Director or Senior Officer

"Thomas Rodriguez Prats"
Signature

Chief Financial Officer
Official Capacity

<i>Issuer Details</i> Name of Issuer Blueberries Medical Corp.	For Month End MARCH 2026	Date of Report YY/MM/DD 2026/04/06
Issuer Address 885 West Georgia Street, Suite 2200, HSBC Building		
City/Province/Postal Code Vancouver, BC V6C 3E8	Issuer Fax No.	Issuer Telephone No.
Contact Name Thomas Rodriguez Prats	Contact Position CFO	Contact Telephone No. +57 3 11 6174 246
Contact Email Address trodriguez@blueberriesmed.com	Web Site Address www.blueberriesmed.com	